EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Pragmatische StudieOpen Access

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

Rocío Montejano, Fernando de la Calle-Prieto, María Velasco, Carlos Guijarro, Javier Queiruga-Parada, María Jiménez-González, Patricia González-Ruano, Patricia Martínez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Ángela Gutiérrez und 20 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac628 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Rocío Montejano und 31 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, Instituto de Investigación del Hospital Universitario La Paz, Cen…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Instituto de Salud Carlos III, Ministry of Innovation and Science of Spain,.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study was designed to evaluate if patients with high risk for severe coronavirus disease 2019 (COVID-19) would benefit from treatment with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) followed by baricitinib in case of hypoxemia and systemic inflammation.

Methods

PANCOVID is an open-label, double-randomized, phase 3 pragmatic clinical trial including adults with symptomatic COVID-19 with ≥2 comorbidities or aged ≥60 years and was conducted between 10 October 2020 and 23 September 2021. In the first randomization, patients received TDF/FTC or no TDF/FTC. In the second randomization, patients with room air oxygen saturation <95% and at least 1 increased inflammatory biomarker received baricitinib plus dexamethasone or dexamethasone alone. The primary endpoint was 28-day mortality. Main secondary endpoint was 28-day disease progression or critical care unit admission or mortality. The trial was stopped before reaching planned sample size due to the decrease in the number of cases and a mortality rate substantially lower than expected.

Results

Of the 355 included participants, 97% were hospitalized at baseline. Overall, 28-day mortality was 3.1%. The 28-day mortality relative risk (RR) for participants treated with TDF/FTC was 1.76 (95% confidence interval [CI], .52–5.91; P = .379); it was 0.42 (95% CI, .11–1.59; P = .201) for those treated with baricitinib. The 28-day RR for the main secondary combined endpoint for participants treated with TDF/FTC was 0.95 (95% CI, .66–1.40; P = .774); it was 0.90 (95% CI, .61–1.33; P = .687) for those treated with baricitinib.

Conclusions

Our results do not suggest a beneficial effect of TDF/FTC; nevertheless, they are compatible with the beneficial effect of baricitinib already established by other clinical trials. Clinical Trials Registration EudraCT: 2020-001156-18.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsCOVID-19AdultHumansTenofovirEmtricitabineCOVID-19 Drug TreatmentDexamethasoneAzetidinesPurinesPyrazolesSulfonamides

Stichwörter der Autor:innen

COVID-19baricitinibemtricitabinetenofovir disoproxil fumarate

Substanzen

TenofovirEmtricitabineAnti-HIV AgentsDexamethasonebaricitinibAzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, Instituto de Investigación del Hospital Universitario La Paz, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Mad…
  • Infectious Diseases, Research Unit, University Hospital Fundación Alcorcón, Madrid, Spain.
  • Internal Medicine Unit, University Hospital Fundación Alcorcón, Rey Juan Carlos University, Madrid, Spain.
  • Clinical Pharmacology Department, La Paz University Hospital, Infectious Diseases Unit, La Paz University Hospital, Instituto de Investigación del Hospital Universitario La Paz, Madrid, Spain.
  • Clinical Pharmacology Department, La Paz University Hospital, La Paz University Hospital, Instituto de Investigación del Hospital Universitario La Paz, Spanish Clinical Research Network, Madrid, Spain.
  • Internal Medicine Department, University Hospital Infanta Sofía, Madrid, Spain.

ORCID-Profile: Pablo Ryan, Cristina Marcelo, José R Arribas

Förderung

  • Instituto de Salud Carlos III
  • Ministry of Innovation and Science of Spain,

Zitieren

APA

Montejano, R., de la Calle-Prieto, F., Velasco, M., Guijarro, C., Queiruga-Parada, J., Jiménez-González, M., González-Ruano, P., Martínez, P., Goikoetxea, A. J., Ibarrola, M., Ciudad, M., Gutiérrez, Á., Torralba, M., Díaz-Brasero, A., Ryan, P., Marcelo, C., Díez, C., Ibarra, S., Merino, E., …, & PANCOVID Study Group (2023). Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac628

Vancouver

Montejano R, de la Calle-Prieto F, Velasco M, Guijarro C, Queiruga-Parada J, Jiménez-González M, et al. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac628

BibTeX
@article{Montejano2023,
  author = {Montejano, Rocío and de la Calle-Prieto, Fernando and Velasco, María and Guijarro, Carlos and Queiruga-Parada, Javier and Jiménez-González, María and González-Ruano, Patricia and Martínez, Patricia and Goikoetxea, Ane Josune and Ibarrola, Marta and Ciudad, Marianela and Gutiérrez, Ángela and Torralba, Miguel and Díaz-Brasero, Ana and Ryan, Pablo and Marcelo, Cristina and Díez, Cristina and Ibarra, Sofía and Merino, Esperanza and Estrada, Vicente and Marcos, Javier and Novella, María and Rivera, María A and Ruiz-Muñoz, Manuel and de Miguel, Marta and Soler, Llanos and Del Álamo, Mikel and Moreno, Santiago and Carcas, Antonio J and Borobia, Alberto M and Arribas, José R and PANCOVID Study Group, PANCOVID Study Group},
  title = {Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac628}
}
Kostenlos starten →